Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01173445 · ClinicalTrials.gov registry record
Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma
A clinical trial of Renal Cell Carcinoma, sponsored by University of Kansas.
- Completed
- Registry status
- 19
- Enrollment target
- 1
- Study location
NCT01173445: Completed study of Renal Cell Carcinoma, sponsored by University of Kansas.
NCT01173445 is a study of Renal Cell Carcinoma that has completed, run by University of Kansas. The registered enrollment target is 19 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01173445, a study of Renal Cell Carcinoma, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if researchers can detect circulating tumor cells (CTC) and circulating endothelial cells (CEC) in the blood.
Primary Outcome
Subject samples will be used to see if CTCs and/or CECs will be valuable and versatile biomarkers for therapeutic response, determination of relapse and survival in patients with renal cell cancer.
Conditions Studied
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-05 |
What the finished NCT01173445 record still lists
NCT01173445 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT01173445 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01173445 about?
NCT01173445 is a clinical study titled "Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma". The purpose of this study is to see if researchers can detect circulating tumor cells (CTC) and circulating endothelial cells (CEC) in the blood.
What is the current status of trial NCT01173445?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2010-07. Estimated completion is 2011-05.
What conditions does trial NCT01173445 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
Who is sponsoring clinical trial NCT01173445?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01173445 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01173445's enrollment target sits among peer trials
19 113th of 121 higher than 9 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
PET/MR for Characterization of Renal Masses (RMs)
RECRUITING
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia